Correction to Novel 19F activatable probe for the detection of matrix metalloprotease-2 activity by MRI/MRS (Molecular Pharmaceutics (2014) 11 (4208?4217) DOI: 10.1021/mp500443x);Novel 19F activatable probe for the detection of matrix metalloprotease-2 activity by MRI/MRS

Molecular Pharmaceutics

Volumn 11, Issue 11, 2014, Pages 4208-4217

  Yue, Xuyi ^a,b,e   Wang, Zhe ^a   Zhu, Lei ^a,b   Wang, Yu ^a,c   Qian, Chunqi ^d   Ma, Ying ^a   Kiesewetter, Dale O ^a   Niu, Gang ^a   Chen, Xiaoyuan ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b XIAMEN UNIVERSITY   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

19F magnetic resonance imaging; 19F magnetic resonance spectroscopy; Activatable probe; Matrix metalloproteases

Indexed keywords

FLUORINE; GELATINASE A; CONTRAST MEDIUM; MMP2 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

AMINO ACID SEQUENCE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SPECIFICITY; FLUORINE NUCLEAR MAGNETIC RESONANCE; IN VITRO STUDY; INCUBATION TIME; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION; SOLUBILITY; SQUAMOUS CELL CARCINOMA CELL; STAUDINGER REACTION; ENZYMOLOGY; HUMAN; METABOLISM; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

CARCINOMA, SQUAMOUS CELL; CONTRAST MEDIA; FLUORINE RADIOISOTOPES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MATRIX METALLOPROTEINASE 2; MOLECULAR IMAGING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 84937984307     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.7b00150     Document Type: Erratum

References (46)

1. Massova, I.; Kotra, L. P.; Fridman, R.; Mobashery, S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J. 1998, 12 (12), 1075-95.
2. Nagase, H.; Woessner, J. F., Jr. Matrix metalloproteinases. J. Biol. Chem. 1999, 274 (31), 21491-4.
3. Folgueras, A. R.; Pendas, A. M.; Sanchez, L. M.; Lopez-Otin, C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. 2004, 48 (5-6), 411-24.
4. Galis, Z. S.; Khatri, J. J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 2002, 90 (3), 251-62.
5. Bauvois, B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim. Biophys. Acta 2012, 1825 (1), 29-36.
6. Klein, G.; Vellenga, E.; Fraaije, M. W.; Kamps, W. A.; de Bont, E. S. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit. Rev. Oncol. Hematol. 2004, 50 (2), 87-100.
7. Curran, S.; Murray, G. I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol. 1999, 189 (3), 300-8.
8. Zucker, S.; Hymowitz, M.; Conner, C.; Zarrabi, H. M.; Hurewitz, A. N.; Matrisian, L.; Boyd, D.; Nicolson, G.; Montana, S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann. N.Y. Acad. Sci. 1999, 878, 212-27.
9. Lee, S. W.; Song, K. E.; Shin, D. S.; Ahn, S. M.; Ha, E. S.; Kim, D. J.; Nam, M. S.; Lee, K. W. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res. Clin. Pract. 2005, 69 (2), 175-9.
10. Maxwell, P. R.; Timms, P. M.; Chandran, S.; Gordon, D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet. Med. 2001, 18 (10), 777-80.
11. DeLano, F. A.; Schmid-Schonbein, G. W. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension 2008, 52 (2), 415-23.
12. Friese, R. S.; Rao, F.; Khandrika, S.; Thomas, B.; Ziegler, M. G.; Schmid-Schonbein, G. W.; O'Connor, D. T. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin. Exp. Hypertens. 2009, 31 (7), 521-33.
13. Zhang, Z.; Fan, J.; Cheney, P. P.; Berezin, M. Y.; Edwards, W. B.; Akers, W. J.; Shen, D.; Liang, K.; Culver, J. P.; Achilefu, S. Activatable molecular systems using homologous near-infrared fluorescent probes for monitoring enzyme activities in vitro, in cellulo, and in vivo. Mol. Pharmaceutics 2009, 6 (2), 416-27.
14. Zhu, L.; Zhang, F.; Ma, Y.; Liu, G.; Kim, K.; Fang, X.; Lee, S.; Chen, X. In vivo optical imaging of membrane-type matrix metalloproteinase (MT-MMP) activity. Mol. Pharmaceutics 2011, 8 (6), 2331-8.
15. Cai, Y.; Zhu, L.; Zhang, F.; Niu, G.; Lee, S.; Kimura, S.; Chen, X. Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs). Mol. Pharmaceutics 2013, 10 (6), 2237-47.
16. Deguchi, J. O.; Aikawa, M.; Tung, C. H.; Aikawa, E.; Kim, D. E.; Ntziachristos, V.; Weissleder, R.; Libby, P. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006, 114 (1), 55-62.
17. Ibarra, J. M.; Jimenez, F.; Martinez, H. G.; Clark, K.; Ahuja, S. S. MMP-Activated fluorescence imaging detects early joint inflammation in collagen-antibody-induced arthritis in CC-chemokine receptor-2-null mice in vivo. Int. J. Inflammation 2011, 2011, 691587.
18. 2 relaxivity for magnetic resonance imaging. Mol. Pharmaceutics 2011, 8 (5), 1970-4.
19. 4 optical nanosensor for imaging protease expressions in vivo. ACS Nano 2011, 5 (4), 3043-51.
20. Cha, E. J.; Jang, E. S.; Sun, I. C.; Lee, I. J.; Ko, J. H.; Kim, Y. I.; Kwon, I. C.; Kim, K.; Ahn, C. H. Development of MRI/NIRF 'activatable' multimodal imaging probe based on iron oxide nanoparticles. J. Controlled Release 2011, 155 (2), 152-8.
21. Ansari, C.; Tikhomirov, G. A.; Hong, S. H.; Falconer, R. A.; Loadman, P. M.; Gill, J. H.; Castaneda, R.; Hazard, F. K.; Tong, L.; Lenkov, O. D.; Felsher, D. W.; Rao, J.; Daldrup-Link, H. E. Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 2014, 10 (3), 566-75 417.
22. Gallo, J.; Kamaly, N.; Lavdas, I.; Stevens, E.; Nguyen, Q. D.; Wylezinska-Arridge, M.; Aboagye, E. O.; Long, N. J. CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance Imaging. Angew. Chem., Int. Ed. 2014, 53, 9550-9554.
23. Huang, C. W.; Li, Z.; Conti, P. S. Radioactive smart probe for potential corrected matrix metalloproteinase imaging. Bioconjugate Chem. 2012, 23 (11), 2159-67.
24. van Duijnhoven, S. M.; Robillard, M. S.; Hermann, S.; Kuhlmann, M. T.; Schafers, M.; Nicolay, K.; Grull, H. Imaging of MMP activity in postischemic cardiac remodeling using radiolabeled MMP-2/9 activatable peptide probes. Mol. Pharmaceutics 2014, 11 (5), 1415-23.
25. Chuang, C. H.; Chuang, K. H.; Wang, H. E.; Roffler, S. R.; Shiea, J. T.; Tzou, S. C.; Cheng, T. C.; Kao, C. H.; Wu, S. Y.; Tseng, W. L.; Cheng, C. M.; Hou, M. F.; Wang, J. M.; Cheng, T. L. In vivo positron emission tomography imaging of protease activity by generation of a hydrophobic product from a noninhibitory protease substrate. Clin. Cancer Res. 2012, 18 (1), 238-47.
26. 19F MRI probes. Chemistry 2013, 19 (38), 12875-83.
27. 19F MRI. Angew. Chem., Int. Ed. 2009, 48 (20), 3641-3.
28. 19F MRI probe to detect protease activity. J. Am. Chem. Soc. 2008, 130 (3), 794-5.
29. 19F NMR/MRI nanoprobes toward rational design and improved sensitivity. J. Am. Chem. Soc. 2011, 133 (30), 11725-31.
30. Ahrens, E. T.; Bulte, J. W. Tracking immune cells in vivo using magnetic resonance imaging. Nat. Rev. Immunol. 2013, 13 (10), 755-63.
31. 1H MR molecular imaging. Angiogenesis 2014, 17 (1), 51-60.
32. 19F MRI and optical imaging. Biomaterials 2010, 31 (27), 7070-7.
33. Yue, X. Y.; Taraban, M. B.; Hyland, L. L.; Yu, Y. B. Avoiding steric congestion in dendrimer growth through proportionate branching: A twist on da Vinci's rule of tree branching. J. Org. Chem. 2012, 77 (20), 8879-8887.
34. Corcoran, M. L.; Hewitt, R. E.; Kleiner, D. E., Jr.; StetlerStevenson, W. G. MMP-2: expression, activation and inhibition. Enzyme Protein 1996, 49 (1-3), 7-19.
35. Ikejiri, M.; Bernardo, M. M.; Bonfil, R. D.; Toth, M.; Chang, M.; Fridman, R.; Mobashery, S. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 2005, 280 (40), 33992-4002.
36. Wolters, M.; Mohades, S. G.; Hackeng, T. M.; Post, M. J.; Kooi, M. E.; Backes, W. H. Clinical perspectives of hybrid proton-fluorine magnetic resonance imaging and spectroscopy. Invest. Radiol. 2013, 48 (5), 341-50.
37. Neubauer, A. M.; Myerson, J.; Caruthers, S. D.; Hockett, F. D.; Winter, P. M.; Chen, J. J.; Gaffney, P. J.; Robertson, J. D.; Lanza, G. M.; Wickline, S. A. Gadolinium-modulated F-19 signals from perfluorocarbon nanoparticles as a new strategy for molecular imaging. Magn. Reson. Med. 2008, 60 (5), 1066-1072.
38. de Vries, A.; Moonen, R.; Yildirim, M.; Langereis, S.; Lamerichs, R.; Pikkemaat, J. A.; Baroni, S.; Terreno, E.; Nicolay, K.; Strijkers, G. J.; Grull, H. Relaxometric studies of gadolinium-functionalized perfluor-ocarbon nanoparticles for MR imaging. Contrast Media Mol. Imaging 2014, 9 (1), 83-91.
39. Nie, L.; Wang, S.; Wang, X.; Rong, P.; Ma, Y.; Liu, G.; Huang, P.; Lu, G.; Chen, X. In vivo volumetric photoacoustic molecular angiography and therapeutic monitoring with targeted plasmonic nanostars. Small 2014, 10 (8), 1585-93.
40. 19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. Curr. Top. Dev. Biol. 2005, 70, 57-76.
41. Chen, J.; Lanza, G. M.; Wickline, S. A. Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2010, 2 (4), 431-40.
42. 19F-MRI nanoprobes with binary ON/OFF pH transitions and chemical-shift barcodes. Angew. Chem., Int. Ed. 2013, 52 (31), 8074-8.
43. 19F MRI probes. Bioconjugate Chem. 2007, 18 (5), 1379-82.
44. 19F NMR probes based on modified gold nanoparticles. Bioorg. Med. Chem. Lett. 2013, 23 (1), 281-6.
45. 19F NMR by redox reactions using a metal complex as a switching module. Bioorg. Med. Chem. 2009, 17 (11), 3818-23.
46. 19F MRI and NIR fluorescence bioimaging. Adv. Healthcare Mater. 2014, 3 (8), 1326-33.